Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Intra-articular corticosteroid Depo Medrol

PreclinicalSmall molecule

IImelda Hospital, Bonheiden

Intra-articular corticosteroid Depo Medrol is one of 2 small molecule programs targeting Adhesive Capsulitis. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adhesive CapsulitisUnknown status

Adhesive CapsulitisPreclinical

Unknown status

Competition

Competitive Landscape

3 competitors in Adhesive Capsulitis

#DrugCompanyPhaseTrials

Celestone

SSchering-Plough

Intra-articular corticosteroid Depo Medrol

IImelda Hospital, Bonheiden

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adhesive Capsulitis1 trial

Corticosteroids and / or Arthrographic Distention in the Treatment of Adhesive Capsulitis

Unknown status·IImelda Hospital, Bonheiden·N/A·NCT01983527·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intra-articular corticosteroid Depo Medrol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intra-articular corticosteroid Depo Medrol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intra-articular corticosteroid Depo Medrol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Imelda Hospital, Bonheiden company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IImelda Hospital, Bonheiden

Related News